Drug Trial Radar · NCT00133874
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
Last checked: Nov 20, 2026Latest source record: Jan 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
520
Actual
Start
Apr 2005
Primary completion
Sep 2005
Study completion Sep 2005
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 24, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
Conditions
- Skin Infections, Bacterial
Interventions
SB-275833 ointment, 1%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical response assessed at end of therapy visit. Clinical success defined by the need for no additional antibiotic treatment.Time frame: 7 Days
Locations
69 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
Kitchener, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
San José, Costa Rica
GSK Investigational Site
Anzin, France
GSK Investigational Site
Bersée, France
GSK Investigational Site
Labarth-Sur-Leze, France
GSK Investigational Site
Martigues, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Seraincourt, France
GSK Investigational Site
Vieux-Condé, France
GSK Investigational Site
Augsburg, Bavaria, Germany
GSK Investigational Site
Gilching, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Mahlow, Brandenburg, Germany
GSK Investigational Site
Duelmen, Lower Saxony, Germany
GSK Investigational Site
Bad Honnef, North Rhine-Westphalia, Germany
GSK Investigational Site
Bonn, North Rhine-Westphalia, Germany
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site
Düsseldorf, North Rhine-Westphalia, Germany
GSK Investigational Site
Gelsenkirchen, North Rhine-Westphalia, Germany
GSK Investigational Site
Kleve-Materborn, North Rhine-Westphalia, Germany
GSK Investigational Site
Krefeld, North Rhine-Westphalia, Germany
GSK Investigational Site
Mülheim, North Rhine-Westphalia, Germany
GSK Investigational Site
Olpe, North Rhine-Westphalia, Germany
GSK Investigational Site
Unna, North Rhine-Westphalia, Germany
GSK Investigational Site
Wuppertal, North Rhine-Westphalia, Germany
GSK Investigational Site
Worms, Rhineland-Palatinate, Germany
GSK Investigational Site
Döbeln, Saxony, Germany
GSK Investigational Site
Dresden, Saxony, Germany
GSK Investigational Site
Reichenbach, Saxony, Germany
GSK Investigational Site
Schmiedeberg, Saxony, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Preetz, Schleswig-Holstein, Germany
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.